ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2162

Immunological Abnormalities in Adult Patients with Parvovirus B19 Infection : A study of 23 Cases

Edouard Pertuiset, Farid Kemiche, Mehdi Yahia and Isabelle Cerf-Payrastre, Rheumatology, Centre Hospitalier René Dubos, Pontoise, France

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Anticardiolipin, Arthritis, Auto-immunity, cryoglobulinemia and parvovirus B19

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Infections, Infection-related Biomarkers and Impact of Biologic Therapies

Session Type: Abstract Submissions (ACR)

Background/Purpose

In adults, parvovirus B19 infection can induce joint symptoms and cutaneous manifestations which are known to be transient most of the time. It has been associated with the production of various antibodies directed against various autoantigens. In this study we report the immunological results in 23 adult patients with parvovirus B19 infection.

Methods

Between 1996 and 2014, 23 adult patients (mean age 35.4 ± 8.9 years; 19 women and 4 men) have been diagnosed with parvovirus B19 infection in our rheumatology department. All patients have been examined by a rheumatologist with a mean delay of 2 weeks after the onset of symptoms and had biological tests including autoimmunity in most cases. In all cases anti-parvovirus B19 IgM were present at a level greater than anti-parvovirus B19 IgG. All patients had arthralgias, 52% of them had mild arthritis and/or tenosynovitis. Cutaneous manifestations were observed in 65% of patients. In all patients, acute joint symptoms resolved in two months, except in one who developed a HLA-B27 negative spondyloarthropathy. Autoimmune tests included search for antinuclear antibodies (ANA) in all patients, rheumatoid factor (RF) in 19 patients, anti-keratine or anti-CCP antibodies in 11 patients, anticardiolipin antibodies (ACL) in 11 patients. Furthermore, C3 and C4 were evaluated in 19 patients and cryoglobulinemia was search in 13 cases.

Results

ESR was 29 ± 17 mm/1sth. Two patients had thrombocytopenia. Five patients (22%) had ANA at moderate levels (160 in 4 cases, 320 in one case) without any specificity (no case of anti-ENA or anti-DNA antibodies). RF was positive in 2 patients (10%) and no patient had anti-CCP antibodies. ACL antibodies were detected in seven cases (63%). In three cases diagnosed before 2009, they were IgG anti-ACL at low levels (20-28 U). Since 2009, our laboratory tests both IgG and IgM ACL antibodies: 4 patients had IgM ACL at levels ranged from 22 to 51 U (normal 0-19), without IgG ACL antibody. A decrease of C3 was observed in one patient (5%) and a decrease of C4 was present in 5 patients (26%). Search for cryoglobulinemia was positive in 6 cases (46%). In five cases it was a type III cryoglobulinemia at low level and in one case these level was too small for identification.

Conclusion

Some immunological abnormalities including ANA, RF, ACL antibodies, low C4 level and cryoglobulinamia are quite often encountered in parvovirus B19 infection in adults with rheumatologic symptoms. The presence of IgM ACL antibodies and mixed type III cryoglobulinemia appears frequent in our most recent experience. These abnormalities are asymptomatic and transient, but can lead to misdiagnosis and highlight some relationships between innate immunity activation and autoimmune response.


Disclosure:

E. Pertuiset,
None;

F. Kemiche,
None;

M. Yahia,
None;

I. Cerf-Payrastre,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/immunological-abnormalities-in-adult-patients-with-parvovirus-b19-infection-a-study-of-23-cases/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology